Search trials



Primary RegistryProtocol numberPublic titleScientific titleType of studyRecruitment statusLast updated
LBCTR2021014721NN9924-4437Efficacy and safety of oral semaglutide versus placebo in children and adolescents with type 2 diabetesEfficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetesInterventionalNot recruiting29/03/2021
LBCTR2024015480NN7533-4470ACENT 1A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell diseaseInterventionalPending01/02/2024
LBCTR2023015204NCT05628389Phone Enabled Implementation of Cessation SupportPhone Enabled Implementation of Cessation SupportInterventionalPending21/11/2022
LBCTR2023065377N/AImpact of Health Literacy on Multiple Patient Variables: A Single-Center Observational Study in LebanonImpact of Health Literacy on Multiple Patient Variables: A Single-Center Observational Study in LebanonObservationalComplete14/06/2023
LBCTR2020030215MS700568_0026Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple SclerosisAn Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical TrialsObservationalComplete11/06/2021
LBCTR2021034759MRX-503An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)InterventionalOther03/03/2021
LBCTR2020063422MRX-502A Placebo-controlled study of Maralixibat in Subjects with Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) – MARCH-PFICInterventionalRecruiting03/03/2020
LBCTR2021124932MO42921VanessaA MULTI-COUNTRY OBSERVATIONAL RETROSPECTIVE STUDY TO EVALUATE THE PREVALENCE OF PD-L1 AND ITS ROLE IN PATIENTS WITH TNBC TREATED WITH SYSTEMIC THERAPYObservationalPending05/12/2021
LBCTR2020033423MO40653IMRealA NON-INTERVENTIONAL, MULTICENTER, MULTIPLE COHORT STUDY INVESTIGATING THE OUTCOMES AND SAFETY OF ATEZOLIZUMAB UNDER REAL-WORLD CONDITIONS IN PATIENTS TREATED IN ROUTINE CLINICAL PRACTICEObservationalRecruiting04/03/2020
LBCTR2019030205MO40628A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCERA RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER_ EUDRACT NUMBER: 2018-002153-30InterventionalComplete27/02/2019
items per page31 - 40 of 174 items